Sanjana Ballal1, Madhav Prasad Yadav1, Chandrasekhar Bal2, Ranjit Kumar Sahoo3, Madhavi Tripathi1. 1. Department of Nuclear Medicine, All India Institute of Medical Sciences, AIIMS, Room No. 59-A, Ansari Nagar, New Delhi, 110029, India. 2. Department of Nuclear Medicine, All India Institute of Medical Sciences, AIIMS, Room No. 59-A, Ansari Nagar, New Delhi, 110029, India. csbal@hotmail.com. 3. Department of Medical Oncology, BR Ambedkar Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Abstract
PURPOSE: The objective of this study was to investigate and present the early results on the efficacy, safety, and quality of life of 225Ac-DOTATATE targeted alpha therapy (TAT) in patients with advanced, progressive, 177Lu-DOTATATE refractory, and somatostatin receptor (SSTR) expressing metastatic GEP-NETs. METHODS: In this prospective study, we recruited patients with metastatic GEP-NETs who were stable or progressive disease on 177Lu-DOTATATE therapy. Systemic TAT using 225Ac-DOTATATE was performed in all the patients with 225Ac-DOTATATE (100 kBq/kg body weight) at an interval of 8 weeks. The primary end point was to assess the objective response (measured by RECIST 1.1 and functional M.D. Anderson criteria). The secondary end points included biochemical response assessment as per the Italian Trials in Medical Oncology (ITMO), adverse event profile as per CTCAE v5.0, and clinical response assessment by the quality of life (assessed with EORTC QLQ-GI.NET21 patient-based questionnaire). RESULTS: Between April 2018 and March 2019, 32 patients (17 females, 15 males, mean age 52 ± 9.2 years, 35-72 years) with either stable disease after completing 177Lu-DOTATATE therapy (14, 44%) or progressive disease on 177Lu-DOTATATE therapy (18, 56%) were included in the study. The morphological response was assessed in 24/32 patients that revealed partial remission in 15 and stable disease in 9. There was no documented disease progression or deaths in the median follow-up of 8 months (range 2-13 months). There was a significant decrease in the plasma chromogranin level post-225Ac-DOTATATE therapy (P < 0.0001). CONCLUSION: Our short-term clinical results indicate 225Ac-DOTATATE TAT as a promising treatment option which adds a new dimension in patients who are refractory to 177Lu-DOTATATE therapy or have reached the maximum prescribed cycles of 177Lu-DOTATATE therapy.
PURPOSE: The objective of this study was to investigate and present the early results on the efficacy, safety, and quality of life of 225Ac-DOTATATE targeted alpha therapy (TAT) in patients with advanced, progressive, 177Lu-DOTATATE refractory, and somatostatin receptor (SSTR) expressing metastatic GEP-NETs. METHODS: In this prospective study, we recruited patients with metastatic GEP-NETs who were stable or progressive disease on 177Lu-DOTATATE therapy. Systemic TAT using 225Ac-DOTATATE was performed in all the patients with 225Ac-DOTATATE (100 kBq/kg body weight) at an interval of 8 weeks. The primary end point was to assess the objective response (measured by RECIST 1.1 and functional M.D. Anderson criteria). The secondary end points included biochemical response assessment as per the Italian Trials in Medical Oncology (ITMO), adverse event profile as per CTCAE v5.0, and clinical response assessment by the quality of life (assessed with EORTC QLQ-GI.NET21 patient-based questionnaire). RESULTS: Between April 2018 and March 2019, 32 patients (17 females, 15 males, mean age 52 ± 9.2 years, 35-72 years) with either stable disease after completing 177Lu-DOTATATE therapy (14, 44%) or progressive disease on 177Lu-DOTATATE therapy (18, 56%) were included in the study. The morphological response was assessed in 24/32 patients that revealed partial remission in 15 and stable disease in 9. There was no documented disease progression or deaths in the median follow-up of 8 months (range 2-13 months). There was a significant decrease in the plasma chromogranin level post-225Ac-DOTATATE therapy (P < 0.0001). CONCLUSION: Our short-term clinical results indicate 225Ac-DOTATATE TAT as a promising treatment option which adds a new dimension in patients who are refractory to 177Lu-DOTATATE therapy or have reached the maximum prescribed cycles of 177Lu-DOTATATE therapy.
Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Sanjana Ballal; Madhav P Yadav; Nishikant A Damle; Ranjit K Sahoo; Chandrasekhar Bal Journal: Clin Nucl Med Date: 2017-11 Impact factor: 7.794
Authors: Tapan K Nayak; Jeffrey P Norenberg; Tamara L Anderson; Eric R Prossnitz; Michael G Stabin; Robert W Atcher Journal: Nucl Med Biol Date: 2007-02 Impact factor: 2.408
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Lisa Bodei; Marta Cremonesi; Chiara M Grana; Nicola Fazio; Simona Iodice; Silvia M Baio; Mirco Bartolomei; Dario Lombardo; Mahila E Ferrari; Maddalena Sansovini; Marco Chinol; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-03 Impact factor: 9.236
Authors: Jeffrey P Norenberg; Boudewijn J Krenning; Inge R H M Konings; Donna F Kusewitt; Tapan K Nayak; Tamara L Anderson; Marion de Jong; Kayhan Garmestani; Martin W Brechbiel; Larry K Kvols Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel Journal: Lancet Date: 2015-12-17 Impact factor: 79.321
Authors: C Kratochwil; F L Giesel; F Bruchertseifer; W Mier; C Apostolidis; R Boll; K Murphy; U Haberkorn; A Morgenstern Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-29 Impact factor: 9.236
Authors: Narges K Tafreshi; Darpan N Pandya; Christopher J Tichacek; Mikalai M Budzevich; Zhen Wang; Jordan N Reff; Robert W Engelman; David C Boulware; Alberto A Chiappori; Jonathan R Strosberg; Haitao Ji; Thaddeus J Wadas; Ghassan El-Haddad; David L Morse Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-26 Impact factor: 9.236
Authors: Karthika J Kadassery; A Paden King; Stanley Fayn; Kwamena E Baidoo; Samantha N MacMillan; Freddy E Escorcia; Justin J Wilson Journal: Bioconjug Chem Date: 2022-06-07 Impact factor: 6.069
Authors: Satya Das; Liping Du; Aimee Schad; Shikha Jain; Aaron Jessop; Chirayu Shah; David Eisner; Dana Cardin; Kristen Ciombor; Laura Goff; Marques Bradshaw; Dominique Delbeke; Martin Sandler; Jordan Berlin Journal: Endocr Relat Cancer Date: 2021-03 Impact factor: 5.678